Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232556 · ClinicalTrials.gov registry record · Phase 3
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 338
- Enrollment target
NCT01232556 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 338 participants.
The verdict
NCT01232556, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 338 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin plus rituximab in relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy. Specifically, the goal is to demonstrate the superiority of this combination compared with an active comparator arm (investigator's choice of rituximab+bendamustine or rituximab+gemcitabine) using the primary endpoint of overall survival.
Interventions
- DRUG Rituximab
- DRUG Inotuzumab ozogamicin
- DRUG rituximab + gemcitabine
- DRUG rituximab +bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2011-04-04 |
| Est. Completion | 2014-03-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232556
The ClinicalTrials.gov registry entry for NCT01232556 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rituximab is the first listed.
NCT01232556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01232556 about?
NCT01232556 is a clinical study titled "A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy". The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin plus rituximab in relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy. Specifically, the goal is to demonstrate the superiority of this combination comp...
What is the current status of trial NCT01232556?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 338 participants. The study started on 2011-04-04. Estimated completion is 2014-03-28.
What interventions are being tested in trial NCT01232556?
The interventions under investigation include: Rituximab (DRUG), Inotuzumab ozogamicin (DRUG), rituximab + gemcitabine (DRUG), rituximab +bendamustine (DRUG).
Who is sponsoring clinical trial NCT01232556?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.